Pharmacogenetic Study of Irinotecan Chemotherapy
This study is aimed at patients with advanced colorectal
cancer receiving first dose of an irinotecan containing regimen.
Develop a model using germline polymophisms in enzymes
involved with irinotecan glucuronidation to predict toxicity and tumour
response after irinotecan therapy.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society